AU2020298737B2 - Methylthioninium as enhancers of the cognitive function - Google Patents

Methylthioninium as enhancers of the cognitive function

Info

Publication number
AU2020298737B2
AU2020298737B2 AU2020298737A AU2020298737A AU2020298737B2 AU 2020298737 B2 AU2020298737 B2 AU 2020298737B2 AU 2020298737 A AU2020298737 A AU 2020298737A AU 2020298737 A AU2020298737 A AU 2020298737A AU 2020298737 B2 AU2020298737 B2 AU 2020298737B2
Authority
AU
Australia
Prior art keywords
compound
therapeutic use
acid
subject
lmtm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020298737A
Other languages
English (en)
Other versions
AU2020298737A1 (en
Inventor
Charles Robert Harrington
Jochen Klein
Gernot Riedel
Karima SCHWAB
Claude Michel Wischik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taurx Therapeutics Management Ltd
Original Assignee
Taurx Therapeutics Management Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taurx Therapeutics Management Ltd filed Critical Taurx Therapeutics Management Ltd
Publication of AU2020298737A1 publication Critical patent/AU2020298737A1/en
Assigned to TauRx Therapeutics Management Ltd reassignment TauRx Therapeutics Management Ltd Request for Assignment Assignors: WISTA LABORATORIES LTD.
Application granted granted Critical
Publication of AU2020298737B2 publication Critical patent/AU2020298737B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D25/00—Details of other kinds or types of rigid or semi-rigid containers
    • B65D25/34—Coverings or external coatings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D2203/00—Decoration means, markings, information elements, contents indicators
    • B65D2203/02—Labels

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Mechanical Engineering (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Composite Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Physiology (AREA)
AU2020298737A 2019-07-01 2020-06-29 Methylthioninium as enhancers of the cognitive function Active AU2020298737B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1909454.9 2019-07-01
GBGB1909454.9A GB201909454D0 (en) 2019-07-01 2019-07-01 Enhancers
PCT/EP2020/068229 WO2021001306A1 (en) 2019-07-01 2020-06-29 Methylthioninium as enhancers of the cognitive function

Publications (2)

Publication Number Publication Date
AU2020298737A1 AU2020298737A1 (en) 2022-02-24
AU2020298737B2 true AU2020298737B2 (en) 2026-03-05

Family

ID=67539959

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020298737A Active AU2020298737B2 (en) 2019-07-01 2020-06-29 Methylthioninium as enhancers of the cognitive function

Country Status (12)

Country Link
US (1) US20220330594A1 (https=)
EP (1) EP3989977A1 (https=)
JP (1) JP7686581B2 (https=)
KR (1) KR20220028045A (https=)
CN (1) CN114096254A (https=)
AU (1) AU2020298737B2 (https=)
BR (1) BR112021025330A2 (https=)
CA (1) CA3143417A1 (https=)
GB (1) GB201909454D0 (https=)
IL (1) IL289341A (https=)
MX (1) MX2021015289A (https=)
WO (1) WO2021001306A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3121169T3 (da) 2006-07-11 2022-02-28 Wista Lab Ltd Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser
DK3826639T3 (da) 2018-07-26 2024-09-23 Wista Lab Ltd Optimeret dosering af diaminophenothiaziner i populationer
KR102856378B1 (ko) 2022-09-30 2025-09-08 주식회사 젬백스앤카엘 4r 타우병증의 치료 또는 예방용 펩티드
AU2024231880A1 (en) 2023-03-03 2025-09-11 Taurx Therapeutics Management Ltd. Diaminophenothiazine for the treatment of microvascular brain disease disease
KR20240176447A (ko) 2023-06-15 2024-12-24 주식회사 젬백스앤카엘 신규 펩티드 및 이의 용도
KR102800994B1 (ko) 2023-11-06 2025-04-29 주식회사 엘지에너지솔루션 무음극 코팅층 및 이를 포함하는 전고체 전지

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008155533A2 (en) * 2007-06-19 2008-12-24 Wista Laboratories Ltd Phenothiazine compounds for treating mild cognitive impairment
WO2018019823A1 (en) * 2016-07-25 2018-02-01 Wista Laboratories Ltd. Administration and dosage of diaminophenothiazines
WO2018041739A1 (en) * 2016-09-01 2018-03-08 Wista Laboratories Ltd. Treatment of dementia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
EP2013191B3 (en) 2006-03-29 2019-02-27 Wista Laboratories Ltd. 3,7-diamino-10h-phenothiazine salts and their use
CA3027974C (en) 2007-10-03 2022-03-15 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines
EA025033B1 (ru) 2011-02-11 2016-11-30 Уиста Лэборэтэриз Лтд. Диаминиевые соли фенотиазина и их применение
EP2705841A1 (en) 2012-09-05 2014-03-12 Pharnext Combinations of nootropic agents for treating cognitive dysfunctions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008155533A2 (en) * 2007-06-19 2008-12-24 Wista Laboratories Ltd Phenothiazine compounds for treating mild cognitive impairment
WO2018019823A1 (en) * 2016-07-25 2018-02-01 Wista Laboratories Ltd. Administration and dosage of diaminophenothiazines
WO2018041739A1 (en) * 2016-09-01 2018-03-08 Wista Laboratories Ltd. Treatment of dementia

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FRANCESCO PANZA, VINCENZO SOLFRIZZI, DAVIDE SERIPA, BRUNO P. IMBIMBO, MADIA LOZUPONE, ANDREA SANTAMATO, CHIARA ZECCA, MARIA ROSARI: "Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease", BIOMED RESEARCH INTERNATIONAL, HINDAWI PUBLISHING CORPORATION, vol. 2016, 1 January 2016 (2016-01-01), pages 1 - 15, XP055397299, ISSN: 2314-6133, DOI: 10.1155/2016/3245935 *
GORDON K. WILCOCK, SERGE GAUTHIER, GIOVANNI B. FRISONI, JIANPING JIA, JIRI H. HARDLUND, HANS J. MOEBIUS, PETER BENTHAM, KARIN A. K: "Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial", JOURNAL OF ALZHEIMER`S DISEASE, IOS PRESS, NL, vol. 61, no. 1, 28 November 2017 (2017-11-28), NL, pages 435 - 457, XP055636963, ISSN: 1387-2877, DOI: 10.3233/JAD-170560 *
JULIO C. ROJAS; ALEKSANDRA K. BRUCHEY; F. GONZALEZ-LIMA;: "Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue", PROGRESS IN NEUROBIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 96, no. 1, 27 October 2011 (2011-10-27), AMSTERDAM, NL, pages 32 - 45, XP028448217, ISSN: 0301-0082, DOI: 10.1016/j.pneurobio.2011.10.007 *
RODRIGUEZ PAVEL; SINGH AMAR P.; MALLOY KRISTEN E.; ZHOU WEI; BARRETT DOUGLAS W.; FRANKLIN CRYSTAL G.; ALTMEYER WILSON B.; GUTIERRE: "Methylene blue modulates functional connectivity in the human brain", BRAIN IMAGING AND BEHAVIOR, SPRINGER US, BOSTON, vol. 11, no. 3, 10 March 2016 (2016-03-10), Boston, pages 640 - 648, XP036260685, ISSN: 1931-7557, DOI: 10.1007/s11682-016-9541-6 *
T. C. BADDELEY, J. MCCAFFREY, J. M. D. STOREY, J. K. S. CHEUNG, V. MELIS, D. HORSLEY, C. R. HARRINGTON, C. M. WISCHIK: "Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 352, no. 1, 18 November 2014 (2014-11-18), pages 110 - 118, XP055384953, DOI: 10.1124/jpet.114.219352 *

Also Published As

Publication number Publication date
GB201909454D0 (en) 2019-08-14
US20220330594A1 (en) 2022-10-20
JP2022539185A (ja) 2022-09-07
WO2021001306A1 (en) 2021-01-07
CA3143417A1 (en) 2021-01-07
KR20220028045A (ko) 2022-03-08
JP7686581B2 (ja) 2025-06-02
IL289341A (en) 2022-02-01
EP3989977A1 (en) 2022-05-04
CN114096254A (zh) 2022-02-25
MX2021015289A (es) 2022-01-18
BR112021025330A2 (pt) 2022-02-01
AU2020298737A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
AU2020298737B2 (en) Methylthioninium as enhancers of the cognitive function
KR102559354B1 (ko) 치매 치료
EP2167095B1 (en) Phenothiazine compounds for treating mild cognitive impairment
AU2010282509B2 (en) Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions
AU2020300792B2 (en) Methylthioninium for use in the treatment of synaptopathies
US20230031369A1 (en) Therapeutic interactions of leucomethylthioninium
RU2824584C2 (ru) Метилтиониний в качестве усилителя когнитивной функции
RU2834773C2 (ru) Терапевтические взаимодействия лейкометилтиониния
Ligsay et al. Overview of targeted double-blind, placebo-controlled clinical trials in fragile X syndrome
CA3034625C (en) Treatment of dementia
HK40003690B (en) Treatment of dementia
WORKS Current
HK1136965A (en) Phenothiazine compounds for treating mild cognitive impairment

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TAURX THERAPEUTICS MANAGEMENT LTD

Free format text: FORMER APPLICANT(S): WISTA LABORATORIES LTD.